Genetic Technologies Limited (ASX: GTG)

About Genetic Technologies Limited

Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.

ISIN

AU000000GTG7

Founded

1987

Listed since

Jan 31, 1988

Exchange

Australian Securities Exchange

Currency

AUD